Suven Life Sciences slumped 14.85% to Rs 268.05 after the company said that its key molecule SUVN-502 (Masupirdine), meant for treatment of Alzheimer, did not meet the pre-specified primary endpoint.
As part of the study, Suven Life tested the drug as a unique triple combination with Donepezil and Memantine on 564 Alzheimer's Disease (AD) patients in the US for at least one year. The trial compared the efficacy and safety of two doses of Masupirdine (50 mg and 100 mg per day) to placebo in moderate AD patients.
Triple therapy of Masupirdine (SUVN-502) with Donepezil and Memantine proof of concept phase 2 study missed its pre-specified primary endpoint.
"We are very disappointed with the outcome of this trial but the findings present an important step forward in further exploration of the potential therapeutic effects of Masupirdine (SUVN-502) in Alzheimer's Disease (AD) and Behavioral & Psychological Symptoms in Dementia (BPSD). We will work with regulators and potential partnering companies in the design and conduct of future studies for further exploration of the potential of Masupirdine (SUVN-502)," said Venkat Jasti, CEO of Suven.
The announcement was made on Saturday, 30 November 2019.
Meanwhile, the S&P BSE Sensex was up 1 point or flat at 40,794.34.
In the past one month, shares of Suven Life Sciences fell 4.64% to its current market price of Rs 268.05, underperforming the Nifty Pharma index's 2.14% rise in the same period.
On the technical front, the stock's RSI (relative strength index) stood at 37.148. The RSI oscillates between zero and 100. Traditionally the RSI is considered overbought when above 70 and oversold when below 30.
The stock was currently trading below its 50-day moving average (DMA) placed at Rs 285.97, but above its 200 DMA placed at Rs 262.43.
Suven Life Sciences' consolidated net profit surged 1,535.90% to Rs 63.31 crore on 206.4% surge in net sales to Rs 274.31 crore in Q2 September 2019 over Q2 September 2018.
Suven Life Sciences is engaged in the business of manufacture and sale of bulk drugs and intermediaries.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.